Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10066-10076
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10066
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10066
Table 2 Treatment-related toxicities
Toxicity | Group treated with TA | Group treated without TA | ||
Grade 1-2, % | Grade 3-4, % | Grade 1-2, % | Grade 3-4, % | |
Hematologic toxicity | ||||
Neutropenia | 2 (13.3) | 2 (13.3) | 5 (33.3) | 3 (20.0) |
Anemia | 3 (20.0) | 2 (13.3) | 4 (26.7) | 1 (6.7) |
Thrombocytopenia | 0 | 0 | 5 (33.3) | 1 (6.7) |
Non-hematologic toxicity | ||||
Nausea/vomiting | 5 (33.3) | 2 (13.3) | 3 (20.0) | 2 (13.3) |
Oral mucositis | 6 (40.0) | 1 (6.7) | 2 (13.3) | 0 |
Anorexia | 8 (53.3) | 0 | 7 (46.7) | 0 |
Neuropathy | 4 (28.5) | 1 (6.7) | 8 (57.1) | 0 |
Diarrhea | 2 (13.3) | 1 (6.7) | 3 (20.0) | 1 (6.7) |
- Citation: Jang HR, Lee HY, Song SY, Lim KH. Clinical outcomes of targeted therapies in elderly patients aged ≥ 80 years with metastatic colorectal cancer. World J Clin Cases 2022; 10(28): 10066-10076
- URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10066.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10066